The top pre-market NASDAQ stock market gainers are: CyberDefender, Lattice Semiconductor, support.com, Cost Plus, Enzon Pharmaceuticals, Cogo Group, Sky-mobi, LJ International, Entropic Communications, and Novavax.
CyberDefender Corp. (CYDE) improved 16.30 percent to $3.14 in the pre-market session.
Lattice Semiconductor Corp. (LSCC) climbed 11.55 percent to $5.70 in the pre-market trading.
support.com, Inc. (SPRT) jumped 9.43 percent to $7.43 in the pre-market session.
Cost Plus Inc. (CPWM) advanced 9.07 percent to $11.79 in the pre-market trading.
Enzon Pharmaceuticals Inc. (ENZN) surged 8.14 percent to $12.62 in the pre-market session. The company announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of its novel oncology product candidates, EZN-2968 and EZN-2208.
The company said both EZN-2968 and EZN-2208 have been shown to down-modulate HIF-1a, a subunit of HIF-1. HIF-1 is frequently over-expressed in cancer cells, where it is involved in the up-regulation of gene products essential for tumor invasion, migration, angiogenesis and production of vascular endothelial growth factor.
Cogo Group, Inc. (COGO) soared 7.73 percent to $8.50 in the pre-market trading. The company said in a regulatory filing that its units Comtech International (Hong Kong) Ltd. and Comtech Broadband Ltd. entered into credit amount contracts with the Macau Branch of Guangdong Development Bank for the purpose of providing short-term trade operation working capital with the maximum loans amount of $20 million and $10 million.
Sky-mobi Ltd. (MOBI) gained 7.69 percent to $5.60 in the pre-market session.
LJ International Inc. (JADE) grew 7.65 percent to $3.80 in the pre-market trading.
Entropic Communications, Inc. (ENTR) rose 7.05 percent to $11.84 in the pre-market trading.
Novavax, Inc. (NVAX) increased 4.69 percent to $2.68 in the pre-market session. The company said its phase I clinical trial to assess a new vaccine candidate to prevent respiratory syncytial virus, or RSV, infection has been cleared by the FDA and is no longer on clinical hold.